Researches

Events

News

PayaVax G79

Inactivated Bivalent PayaVax G79 Vaccine Highly Virulent Newcastle Disease Avian Influenza & Virus Genotype G7 H9N2

More Info

PayaVax G7

Inactivated Bivalent PayaVax G79 Vaccine Highly Virulent Newcastle Disease Avian Influenza & Virus Genotype G7 H9N2

More Info

PayaVax H9

Inactivated Bivalent PayaVax G79 Vaccine Highly Virulent Newcastle Disease Avian Influenza & Virus Genotype G7 H9N2

More Info

Paya Vaccine Tavana

Paya Vaccine Tavana Knowledge-Based Company began its research in the field of poultry vaccine production in 2016 (1395) and established its production facility in 2022 (1401). With the efforts of academic experts and elites, the company manufactures its vaccines and products in accordance with the highest international standards and Good Manufacturing Practices (GMP).

Paya Vaccine Tavana is the first company in Iran to produce vaccines based on the highly virulent Newcastle disease virus (NDV) genotype VII, using indigenous virus seeds. By utilizing advanced technologies and modern equipment, the company has succeeded in producing high-quality vaccines that comply with international standards. Paya Vaccine Tavana is committed to improving poultry health in the country and reducing dependency on imports through its scientifically backed operations.

Products

PayaVax G79

View

PayaVax G79 is an innovative inactivated vaccine designed as a bivalent solution to protect poultry against Newcastle Disease Genotype VII (GVII) and Avian Influenza H9N2. This vaccine is developed from local virus strains and produced in accordance with international standards, including GMP (Good Manufacturing Practices) principles. The first bivalent vaccine produced in Iran Effectively stimulates the immune system Long-lasting immunity Produced according to global standards Approved by the Iranian Veterinary Organization

PayaVax G7

View

PayaVax G-VII is an inactivated monovalent vaccine developed to provide immunity in poultry against highly virulent Newcastle Disease caused by Genotype G-VII. This vaccine is produced using a local virus strain and manufactured in compliance with international standards, including GMP (Good Manufacturing Practices) guidelines. Effective immunity Flexible application Long-lasting protection Manufactured according to international standards Approved by the Iranian Veterinary Organization

PayaVax H9

View

PayaVax H9 is a monovalent inactivated vaccine designed to induce immunity in poultry against avian influenza caused by the H9N2 subtype. This vaccine is produced using a locally isolated virus strain and is manufactured in compliance with international standards, including Good Manufacturing Practices (GMP). Key Features: Effective immunity Optimized formulation Long-lasting protection Produced according to global standards Approved by the Veterinary Organization

Vision and Mission

A regional benchmark in the vaccine industry leading sustainable innovation by 2029.

Paya Vaccine Tavana, grounded in unparalleled scientific expertise, relentless technological innovation, and an unwavering commitment to the highest global standards, defines its mission as pioneering the development and delivery of superior vaccine and bioproduct solutions for the poultry industry. With a visionary and accountable approach, we are steadfast in advancing poultry health, enhancing food security, and championing environmental sustainability across national, regional, and international landscapes.

By driving productivity gains and elevating biological benchmarks, we position ourselves as a catalyst for transformative and sustainable progress within the global poultry farming sector

Paya Vaccine Tavana

Vision and Mission

A regional benchmark in the vaccine industry leading sustainable innovation by 2029.

By driving productivity gains and elevating biological benchmarks, we position ourselves as a catalyst for transformative and sustainable progress within the global poultry farming sector